Novartis delivered sales growth and core margin expansion in Q3; raised FY core operating income guidance
Ad hoc announcement pursuant to Art. 53 LR Third quarter Q3 net sales grew +4% (cc¹, +4% USD),…
Novartis RemIND data at EAACI show Rhapsido® potential as first targeted therapy for chronic inducible urticaria (CIndU)
Rhapsido demonstrated statistically significant and clinically meaningful symptom control in twice as many patients vs placebo1, with favorable…
Pluvicto™ demonstrated consistent efficacy across key patient subgroups in metastatic hormone-sensitive prostate cancer
Improved radiographic progression-free survival (rPFS) regardless of disease volume or metastatic presentation achieved with Pluvicto plus standard of…
Novartis agrees to acquire a pan-mutant-selective PI3Kα inhibitor, strengthening its breast cancer pipeline
Proposed acquisition supports the Novartis oncology strategy in hormone receptor positive, human epidermal growth factor receptor two-negative (HR+/HER2-)…
Novartis to build new radioligand therapy site in Denton, Texas, delivering more next‑generation treatments to patients
Facility expected to be operational in 2028 in Dallas-Fort Worth area, expanding largest RLT manufacturing network in USSite…
Novartis successfully completes acquisition of Avidity Biosciences, strengthening late-stage neuroscience pipeline and advancing xRNA strategy
Adds Avidity’s differentiated muscle-directed Antibody Oligonucleotide Conjugates (AOC) platform and three late-stage programs to industry-leading neuromuscular pipelinePotentially unlocks…
Novartis to build new radioligand therapy site in Denton, Texas, delivering more next‑generation treatments to patients
Facility expected to be operational in 2028 in Dallas-Fort Worth area, expanding largest RLT manufacturing network in USSite…
Novartis presents Rhapsido® (remibrutinib) data at AAAAI, showing potential beyond chronic spontaneous urticaria (CSU)
Analyses from REMIX-1 & -2 studies on CSU disease control and early symptom relief will be presented Phase…
Novartis remibrutinib first therapy to achieve Phase III primary endpoint in chronic inducible urticaria (CIndU)
Statistically significant and clinically meaningful results seen in RemIND trial with complete responses achieved in 3 CIndU types1Remibrutinib,…
Novartis breaks ground on new global Biomedical Research center in San Diego to accelerate drug discovery
New facility will enable end‑to‑end discovery across key disease areas and technology platforms, joining existing global research sites…
Novartis ianalumab receives FDA Breakthrough Therapy designation for Sjögren’s disease
Designation based on clinical evidence supporting potential of ianalumab in Sjögren’s disease, including phase III trials1Distinction expedites development…
Novartis and US government reach agreement on lowering drug prices in the US
Novartis agrees to take actions aimed at meeting US Administration priorities for drug pricingAdditional Novartis medicines will be…